Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.

@article{Zhao2002ComparisonOT,
  title={Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.},
  author={Sean Z Zhao and Thomas Burke and Andrew A Whelton and Heather von Allmen and S. Christine Henderson},
  journal={The American journal of managed care},
  year={2002},
  volume={8 15 Suppl},
  pages={S392-400}
}
OBJECTIVE To evaluate the baseline cardiovascular (CV) risk of hypertensive patients newly starting cyclooxygenase (COX)-2-specific inhibitors (celecoxib or rofecoxib) or nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS Cross-sectional analysis was performed based on real-life practice data contained in the LifeLink Integrated Claims Solutions employer claims database. Patients who newly received treatment of celecoxib, rofecoxib, ibuprofen, naproxen, or diclofenac between… CONTINUE READING